FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Sandoz Files 2nd Biosimilar App for Amgen Drug

[ Price : $8.95]

FDA accepts a Sandoz BLA (351(k) pathway) for a proposed biosimilar to Amgens Enbrel (etanercept), indicated for treating a range ...

Merck Gains Accelerated Approval for Keytruda in Lung Cancer

[ Price : $8.95]

FDA grants Merck accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lun...

510(k) Blues: Morcellator Activist Calls for Shurens Resignation

[ Price : $8.95]

Philadelphia cardiothoracic surgeon Hooman Norchashm meets with CDRH director Jeffrey Shuren and calls for his resignation over hi...

Comments Sought on PDUFA Workload Adjuster

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on a consulting firms assessment of the Prescription Drug User Fee Act Workload Adjust...

Comments Reopened on BE Assessment of Veterinary Drugs

[ Price : $8.95]

Federal Register Notice: FDA reopens the comment period on in vitro methods used to assess bioequivalence of nonsystemically absor...

ICH Guidance on Efficacy Component in CTD Format

[ Price : $8.95]

Federal Register Notice: FDA releases a draft ICH guidance: M4E(R2): The CTD Efficacy.

Amicus Delays Fabry Disease NDA Due to FDA Data Request

[ Price : $8.95]

Amicus Therapeutics delays its plans to submit an NDA by the end of the year for migalastat, indicated for treating Fabry disease,...

RegenxBio Rare Disease Therapy Wins Orphan Status

[ Price : $8.95]

FDA grants RegenxBio an orphan drug designation for RGX-111 for treating mucopolysaccharidosis Type 1.

CDRH Approves Dupont Transition Tyvek

[ Price : $8.95]

CDRH says Dupont Protection Technologies has demonstrated that its new (transition) Tyvek product is functionally equivalent to ex...

House Committee Continues Probe on FDA-inspected NIH Facility

[ Price : $8.95]

An ongoing House Energy and Commerce Committee investigation on management concerns at the NIH Clinical Center Pharmaceutical Deve...